• Nasdaq Hits Lowest Level Since Jan 15   Tuesday, 26 Feb 2013 | 1:48 PM ET
    Nasdaq Hits Lowest Level Since Jan 15

    It is the 95th consecutive trading session in which Apple shares trade below its 50-day moving average, reports CNBC's Seema Mody.

  • BlackBerry Shares Up   Monday, 25 Feb 2013 | 3:43 PM ET
    BlackBerry Shares Up

    CNBC's Seema Mody reports BlackBerry is up today after reports that BBerry 10 is selling faster than expected.

  • J&J Knew About Widespread Hip Implant Failures: Audit Wednesday, 23 Jan 2013 | 9:52 AM ET
    A Smart Bet on Johnson & Johnson?

    An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.

  • Top Biotech Trades   Thursday, 10 Jan 2013 | 5:53 PM ET
    Top Biotech Trades

    Biotech stocks are outperforming the major indices, and are up 3 percent over the past week. CNBC's Seema Mody is tracking which stocks are trending on Twitter.

  • Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.

  • Charles River Laboratories CEO on Drug Development   Wednesday, 9 Jan 2013 | 6:25 PM ET
    Charles River Laboratories CEO on Drug Development

    Charles River Laboratories CEO James Foster discusses competition in the drug market, drug patents and where his business is headed in 2013.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET
    'Rare Good News' on Health Care Retirement Savings: Study

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • Health Care Stocks For an Ailing Portfolio   Wednesday, 9 Jan 2013 | 7:35 AM ET
    Health Care Stocks For an Ailing Portfolio

    "As a group, biotech is the place to be this year," said," Les Funtleyder, Poliwogg fund manager, discussing where to find attractive health care opportunities in 2013.

  • BioMarin's CEO On Its Product Pipeline   Tuesday, 8 Jan 2013 | 2:20 PM ET
    BioMarin's CEO On Its Product Pipeline

    The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.

  • Biotech Stocks Rally   Tuesday, 8 Jan 2013 | 1:32 PM ET
    Biotech Stocks Rally

    CNBC's Seema Mody reports the pharmaceutical and biotech sectors rally as the JPMorgan conference kicks off its second day.

  • Building the Next Big Biotech   Monday, 7 Jan 2013 | 10:20 AM ET
    Building the Next Big Biotech

    Richard Pops, chairman & CEO at Alkermes, talks with CNBC's David Faber about positive developments in two key treatments in the company's pipeline.

  • US Clears DNA Firm’s Acquisition by Chinese Monday, 31 Dec 2012 | 11:56 AM ET

    The U.S. has given national security clearance to the purchase of an American DNA sequencing company by a Chinese firm, The New York Times reports.

  • McAfee: I Am Innocent   Tuesday, 13 Nov 2012 | 2:50 PM ET
    McAfee: I Am Innocent

    Anti-virus software pioneer John McAfee is now firing back, reports CNBC's Robert Frank.

  • DuPont to Cut 1,500 Jobs as Earnings Miss Estimates Tuesday, 23 Oct 2012 | 11:02 AM ET
    Korean Firm Indicted in Alleged Theft of DuPont Secrets

    DuPont reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday, and announced plans to cut 1,500 jobs.

  • Why Investors Like Pharma Stocks   Monday, 8 Oct 2012 | 2:23 PM ET
    Why Investors Like Pharma Stocks

    Pharmaceuticals continue to be an attractive sector for earnings and dividend growth, and CNBC's Seema Mody reports on how companies like Pfizer are faring.

  • Biotech, Pharma Show Healthy Gains   Monday, 8 Oct 2012 | 7:55 AM ET
    Biotech, Pharma Show Healthy Gains

    If you're looking for beta, biotech might be your answer, reports CNBC's Seema Mody.

  • Healthcare cost

    Thanks to several rounds of cost cutting and new product launches, cash balances across the pharma sector are increasing — because one analyst said we should see more cash being returned to shareholders via dividend.

  • Savient Bulls Come Back for More Wednesday, 19 Sep 2012 | 7:30 AM ET

    Savient Pharmaceuticals has been taken to the woodshed, but recently it’s turned bullish.

  • Biotech—Outperforming for the Right Reasons Monday, 17 Sep 2012 | 4:38 PM ET

    The NYSE Arca Biotech index spacer hit an all-time high Monday, as investors continue to seek out the group for its above average growth prospects.

  • AstraZeneca Poaches Genentech Boss From Roche Tuesday, 28 Aug 2012 | 2:04 AM ET
    AstraZeneca Poaches Genentech Boss From Roche

    AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.